Skip to content

Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women

Low Dose Estriol With Lactobacilli (Gynoflor) Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized, Open, Parallel-Group Study

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00900653
Enrollment
142
Registered
2009-05-13
Start date
2009-05-31
Completion date
2010-07-31
Last updated
2009-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Tract Infections

Keywords

urinary tract infections, postmenopause, lactobacillus, estriol

Brief summary

Recurrent urinary tract infections (UTI) are a problem for postmenopausal women. The aim of this trial is to evaluate the effectiveness of lactobacilli in combination with low dose estriol for preventing recurrent urinary tract infections in postmenopausal women.

Interventions

DRUGGynoflor E (low dose estriol with lactobacillus)

The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Postmenopausal woman * History of urinary tract infection * Agree to abstain from self-medication with antibiotics for UTI symptoms * Agree to abstain from the use of any other intra-vaginal product * Capable of providing informed consent

Exclusion criteria

* Ovarian cancer, cervical cancer, breast cancer * Estrogen treatment within last 2 years * Vaginal bleeding * Antibiotic therapy fewer than three days prior to randomization visit * Known congenital urologic or gynecologic abnormalities * Indwelling urinary catheter * Thromboembolic disease * Uncompensated liver disease * Immunosuppressive drug within 60 days

Design outcomes

Primary

MeasureTime frame
Incidence of urinary tract infection6 months

Secondary

MeasureTime frame
vaginal pH6 months
lactobacillus colonization6 months

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026